SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    H. Wedemeyer, A. S. Duberg, M. Buti, W. M. Rosenberg, S. Frankova, G. Esmat, N. Örmeci, H. Van Vlierberghe, M. Gschwantler, U. Akarca, S. Aleman, İ. Balık, T. Berg, F. Bihl, M. Bilodeau, A. J. Blasco, C. E. Brandão Mello, P. Bruggmann, F. Calinas, J. L. Calleja, H. Cheinquer, P. B. Christensen, M. Clausen, H. S. M. Coelho, M. Cornberg, M. E. Cramp, G. J. Dore, W. Doss, M. H. El-Sayed, G. Ergör, C. Estes, K. Falconer, J. Félix, M. L. G. Ferraz, P. R. Ferreira, J. García-Samaniego, J. Gerstoft, J. A. Giria, F. L. Gonçales, M. Guimarães Pessôa, C. Hézode, S. J. Hindman, H. Hofer, P. Husa, R. Idilman, M. Kåberg, K. D. E. Kaita, A. Kautz, S. Kaymakoglu, M. Krajden, H. Krarup, W. Laleman, D. Lavanchy, P. Lázaro, R. T. Marinho, P. Marotta, S. Mauss, M. C. Mendes Correa, C. Moreno, B. Müllhaupt, R. P. Myers, V. Nemecek, A. L. H. Øvrehus, J. Parkes, K. M. Peltekian, A. Ramji, H. Razavi, N. Reis, S. K. Roberts, F. Roudot-Thoraval, S. D. Ryder, R. Sarmento-Castro, C. Sarrazin, D. Semela, M. Sherman, G. E. Shiha, J. Sperl, P. Stärkel, R. E. Stauber, A. J. Thompson, P. Urbanek, P. Van Damme, I. Thiel, D. Vandijck, W. Vogel, I. Waked, N. Weis, J. Wiegand, A. Yosry, A. Zekry, F. Negro, W. Sievert, E. Gower, Strategies to manage hepatitis C virus (HCV) disease burden, Journal of Viral Hepatitis, 2014, 21,
  2. 2
    Clara T. M. M. de Kanter, Joost P. H. Drenth, Joop E. Arends, Henk W. Reesink, Marc van der Valk, Robert J. de Knegt, David M. Burger, Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations, Clinical Pharmacokinetics, 2014, 53, 5, 409

    CrossRef

  3. 3
    Christopher Koh, T. Jake Liang, What is the future of ribavirin therapy for hepatitis C?, Antiviral Research, 2014, 104, 34

    CrossRef

  4. 4
    Dinesh Jothimani, George M. Chandy, Hari Conjeevaram, A new era in the treatment of chronic hepatitis C infection, Indian Journal of Gastroenterology, 2013, 32, 2, 71

    CrossRef

  5. 5
    Sandra Bodeau, Charlotte Durand-Maugard, Anne-Sophie Lemaire-Hurtel, Catherine François, Sandrine Castelain, François Helle, Michel Andréjak, Eric Nguyen-Khac, Gilles Duverlie, Etienne Brochot, The End-of-Treatment Ribavirin Concentration Predicts Hepatitis C Virus Relapse, Therapeutic Drug Monitoring, 2013, 35, 6, 791

    CrossRef

  6. 6
    David Padua, Sherona Bau, Sammy Saab, Treating Chronic Hepatitis C Viral Infection: Rethinking Dose Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents, Current Hepatitis Reports, 2013, 12, 1, 13

    CrossRef

  7. 7
    I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad, J. Schulz, A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C, Journal of Viral Hepatitis, 2012, 19,
  8. 8
    F. Stickel, B. Helbling, M. Heim, A. Geier, C. Hirschi, B. Terziroli, K. Wehr, A. De Gottardi, F. Negro, T. Gerlach, Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C, Journal of Viral Hepatitis, 2012, 19, 2
  9. 9
    Peter Karayiannis, Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis, Scientifica, 2012, 2012, 1

    CrossRef

  10. 10
    Patrick Marcellin, Hugo Cheinquer, Manuela Curescu, Geoffrey M. Dusheiko, Peter Ferenci, Andrzej Horban, Donald Jensen, Gabriella Lengyel, Alessandra Mangia, Denis Ouzan, Massimo Puoti, Maribel Rodriguez-Torres, Mitchell L. Shiffman, Manuela Schmitz, Fernando Tatsch, Mario Rizzetto, High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials, Hepatology, 2012, 56, 6
  11. 11
    Maribel Rodríguez-Torres, Deana Hallman, Impact of Ethnicity and Race on Treatment Response: Past, Present and Future, Current Hepatitis Reports, 2012, 11, 3, 128

    CrossRef

  12. 12
    Anu Osinusi, Susanna Naggie, Seerat Poonia, Martin Trippler, Zonghui Hu, Emily Funk, Joerg Schlaak, Dawn Fishbein, Henry Masur, Michael Polis, Shyam Kottilil, ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV, Journal of Medical Virology, 2012, 84, 7
  13. 13
    Maribel Rodriguez-Torres, Jihad Slim, Laveeza Bhatti, Richard Sterling, Mark Sulkowski, Tarek Hassanein, Rosário Serrão, Ricard Sola, Anne Bertasso, Sharon Passe, and, Saray Stancic, Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial, HIV Clinical Trials, 2012, 13, 3, 142

    CrossRef

  14. 14
    Matthew M. Riggs, Timothy T. Bergsma, James A. Rogers, Marc R. Gastonguay, G. Mani Subramanian, Cecil Chen, Matt Devalaraja, Alfred E. Corey, Haiying Sun, Jing Yu, Daniel S. Stein, Population Pharmacokinetics and Exposure-Response of Albinterferon Alfa-2b, The Journal of Clinical Pharmacology, 2012, 52, 4
  15. 15
    Ezequiel Ridruejo, Predictors of response to chronic hepatitis C treatment, Future Virology, 2012, 7, 11, 1089

    CrossRef

  16. 16
    Mary Jane Burton, Michael J. Passarella, Brendan M. McGuire, Telaprevir and Boceprevir in African Americans with Genotype 1 Chronic Hepatitis C, Southern Medical Journal, 2012, 105, 8, 431

    CrossRef

  17. 17
    Milos Opravil, Maribel Rodriguez-Torres, Jürgen Rockstroh, Eric Snoeck, Raymond T. Chung, Andreas Tietz, Francesca J. Torriani, The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV, HIV Clinical Trials, 2012, 13, 1, 33

    CrossRef

  18. 18
    Milos Opravil, Maribel Rodriguez-Torres, Jürgen Rockstroh, Eric Snoeck, Raymond T. Chung, Andreas Tietz, Francesca J. Torriani, The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV, HIV Clinical Trials, 2012, 13, 1, 33

    CrossRef

  19. 19
    Helen S Yee, Michael F Chang, Christine Pocha, Joseph Lim, David Ross, Timothy R Morgan, Alexander Monto, Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office, The American Journal of Gastroenterology, 2012, 107, 5, 669

    CrossRef

  20. 20
    Stéphane Chevaliez, Antiviral Activity of the new DAAs for the Treatment of Hepatitis C Virus Infection: Virology and Resistance, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S46

    CrossRef

  21. 21
    Mary Jane Burton, Imran Sunesara, Alan Penman, Huan Pham, Nora Oliver, Casey A. Young, Novell McGloster, Brendan M. McGuire, Comparing the Aspartate Aminotransferase (AST) to Platelet Ratio Index (APRI) Between African American and White Veterans with Chronic Hepatitis C, Southern Medical Journal, 2011, 104, 5, 309

    CrossRef

  22. 22
    Paulina Deming, Sanjeev Arora, Taribavirin in the treatment of hepatitis C, Expert Opinion on Investigational Drugs, 2011, 20, 10, 1435

    CrossRef

  23. 23
    Ira M. Jacobson, John G. McHutchison, Geoffrey Dusheiko, Adrian M. Di Bisceglie, K. Rajender Reddy, Natalie H. Bzowej, Patrick Marcellin, Andrew J. Muir, Peter Ferenci, Robert Flisiak, Jacob George, Mario Rizzetto, Daniel Shouval, Ricard Sola, Ruben A. Terg, Eric M. Yoshida, Nathalie Adda, Leif Bengtsson, Abdul J. Sankoh, Tara L. Kieffer, Shelley George, Robert S. Kauffman, Stefan Zeuzem, Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection, New England Journal of Medicine, 2011, 364, 25, 2405

    CrossRef

  24. 24
    Andreas Maieron, Sigrid Metz-Gercek, Franz Hackl, Alexander Ziachehabi, Harri Fuchsteiner, Christoph Luger, Helmut Mittermayer, Rainer Schöfl, Antiviral treatment of chronic hepatitis C in clinical routine, Wiener klinische Wochenschrift, 2010, 122, 7-8, 237

    CrossRef

  25. 25
    Raymond T. Chung, Fred F. Poordad, Tarek Hassanein, Xiaolei Zhou, Ellen Lentz, Avinash Prabhakar, Adrian M. Di Bisceglie, Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C, Hepatology, 2010, 52, 6
  26. 26
    M. Rodriguez-Torres, F. Torriani, J. Rockstroh, J. Depamphilis, G. Carosi, D.T. Dieterich, Degree of Viral Decline Early in Treatment Predicts Sustained Virological Response in HCV-HIV Coinfected Patients Treated with Peginterferon Alfa-2a and Ribavirin, HIV Clinical Trials, 2010, 11, 1, 1

    CrossRef

  27. 27
    M. Rodriguez-Torres, F. Torriani, J. Rockstroh, J. Depamphilis, G. Carosi, D.T. Dieterich, Degree of Viral Decline Early in Treatment Predicts Sustained Virological Response in HCV-HIV Coinfected Patients Treated with Peginterferon Alfa-2a and Ribavirin, HIV Clinical Trials, 2010, 11, 1, 1

    CrossRef

  28. 28
    J Michael Estep, Zobair M Younossi, Hepatitis C and metabolic syndrome, Expert Review of Endocrinology & Metabolism, 2010, 5, 2, 209

    CrossRef

  29. 29
    Daniel E. Brady, Dawn M. Torres, Jong W. An, John A. Ward, Eric Lawitz, Stephen A. Harrison, Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized, Multicenter, Open-Label Study, Clinical Gastroenterology and Hepatology, 2010, 8, 1, 66

    CrossRef

  30. 30
    Vincent Mallet, Anaïs Vallet-Pichard, Stanislas Pol, New trends in hepatitis C management, La Presse Médicale, 2010, 39, 4, 446

    CrossRef

  31. 31
    V. Pattullo, N. C. Ravindran, T. Mazzulli, D. K. H. Wong, E. J. Heathcote, Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C, Journal of Viral Hepatitis, 2010, 17, 12
  32. 32
    Venessa Pattullo, E. Jenny Heathcote, David K. H. Wong, Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C, Hepatology International, 2010, 4, 4, 723

    CrossRef

  33. 33
    Timothy J. S. Cross, Mohammed M. Rashid, Philip A. Berry, Phillip M. Harrison, The importance of steatosis in chronic hepatitis C infection and its management: A review, Hepatology Research, 2010, 40, 3
  34. 34
    Okba Haj-Ali Saflo, Jesús Miguel Hernández Guijo, Coste-eficacia del tratamiento de la hepatitis C crónica en España, Gastroenterología y Hepatología, 2009, 32, 7, 472

    CrossRef

  35. You have free access to this content35
    Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff, Diagnosis, management, and treatment of hepatitis C: An update, Hepatology, 2009, 49, 4
  36. 36
    Paul Marotta, Dietrich Hueppe, Elmar Zehnter, Paul Kwo, Ira Jacobson, Efficacy of Chronic Hepatitis C Therapy in Community-Based Trials, Clinical Gastroenterology and Hepatology, 2009, 7, 10, 1028

    CrossRef

  37. 37
    A. K. Mathur, C. J. Sonnenday, R. M. Merion, Race and Ethnicity in Access to and Outcomes of Liver Transplantation: A Critical Literature Review, American Journal of Transplantation, 2009, 9, 12
  38. 38
    Julian Schulze zur Wiesch, Ansgar W. Lohse, Results of the IDEAL trial: “Mirror, mirror on the wall … Which's the fairest peg-interferon of them all?”, Hepatology, 2009, 50, 6
  39. 39
    N. Hiramatsu, T. Oze, T. Yakushijin, Y. Inoue, T. Igura, K. Mochizuki, K. Imanaka, A. Kaneko, M. Oshita, H. Hagiwara, E. Mita, T. Nagase, T. Ito, Y. Inui, T. Hijioka, K. Katayama, S. Tamura, H. Yoshihara, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi, Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin, Journal of Viral Hepatitis, 2009, 16, 8
  40. 40
    Ilan S. Weisberg, Ira M. Jacobson, Telaprevir: Hope on the Horizon, Getting Closer, Clinics in Liver Disease, 2009, 13, 3, 441

    CrossRef

  41. 41
    Maribel Rodríguez-Torres, Chronic hepatitis C in minority populations, Current Hepatitis Reports, 2008, 7, 4, 158

    CrossRef

  42. 42
    Richard Njouom, Michèle Tagni Sartre, Isabelle Timba, Eric Nerrienet, Patrice Tchendjou, Christophe Pasquier, Dominique Rousset, Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C, Journal of Medical Virology, 2008, 80, 12
  43. 43
    Kerry N. Whitt, Jaquelyn F. Fleckenstein, Hepatitis C in African Americans, Current Hepatitis Reports, 2008, 7, 4, 139

    CrossRef

  44. 44
    M. Gambarin-Gelwan, I. M. Jacobson, Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C, Journal of Viral Hepatitis, 2008, 15, 9
  45. 45
    Josep Mallolas, Montserrat Laguno, Pegylated IFN-α2bplus ribavirin for treatment-naive patients coinfected with HCV and HIV, Expert Review of Anti-infective Therapy, 2008, 6, 3, 281

    CrossRef

  46. 46
    Chen-Hua Liu, Chun-Jen Liu, Chih-Lin Lin, Cheng-Chao Liang, Shih-Jer Hsu, Sheng-Shun Yang, Ching-Sheng Hsu, Tai-Chung Tseng, Chia-Chi Wang, Ming-Yang Lai, Jun-Herng Chen, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao, Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial, Clinical Infectious Diseases, 2008, 47, 10, 1260

    CrossRef

  47. 47
    Andrea E. Reid, Viral hepatitis in African Americans, Current Hepatitis Reports, 2008, 7, 3, 120

    CrossRef

  48. 48
    Mitchell L. Shiffman, Cytopenias: How they Limit Therapy and Potential Correction,
  49. 49
    Andrew J. Muir, HCV and Racial Differences,